Arcellx (ACLX) Research & Development (2021 - 2025)
Arcellx's (ACLX) quarterly Research & Development came in at $34.1 million in Q4 2025, down 23.64% year-on-year from $44.6 million in Q4 2024, and down 2.83% quarter-over-quarter from $35.1 million in Q3 2025.
Arcellx (ACLX) Research & Development (2021 - 2025) Analysis & Trends
Arcellx's Research & Development history runs 5 years deep, the most recent figure standing at $34.1 million for Q4 2025.
- On a quarterly basis, Research & Development fell 23.64% year-over-year to $34.1 million in Q4 2025; TTM through Dec 2025 was $157.6 million, a 0.33% change from a year earlier, with the FY2025 full-year figure at $157.6 million, changed 0.33% from the prior year.
- Research & Development slipped to $34.1 million in Q4 2025 per ACLX's latest filing, from $35.1 million in the prior quarter.
- Across five years, Research & Development topped out at $83.5 million in Q3 2022 and bottomed at $8.5 million in Q1 2021.
- The 5-year median for Research & Development is $32.6 million (2023), against an average of $32.2 million.
- Across the five-year window, Research & Development surged 577.27% in 2022 and slumped 47.52% in 2023, its largest moves.
- Year by year, Research & Development stood at $13.4 million in 2021, then jumped by 93.69% to $25.9 million in 2022, then climbed by 10.95% to $28.8 million in 2023, then soared by 55.12% to $44.6 million in 2024, then decreased by 23.64% to $34.1 million in 2025.
- Per Business Quant, the three latest ACLX Research & Development figures stand at $34.1 million (Q4 2025), $35.1 million (Q3 2025), and $37.6 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 34.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.10 Mn |
| Sep 30, 2025 | 35.09 Mn |
| Jun 30, 2025 | 37.63 Mn |
| Mar 31, 2025 | 50.80 Mn |
| Dec 31, 2024 | 44.65 Mn |
| Sep 30, 2024 | 39.17 Mn |
| Jun 30, 2024 | 40.95 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | 28.78 Mn |
| Sep 30, 2023 | 43.81 Mn |
| Jun 30, 2023 | 28.33 Mn |
| Mar 31, 2023 | 32.93 Mn |
| Dec 31, 2022 | 25.94 Mn |
| Sep 30, 2022 | 83.47 Mn |
| Jun 30, 2022 | 22.08 Mn |
| Mar 31, 2022 | 18.06 Mn |
| Dec 31, 2021 | 13.39 Mn |
| Sep 30, 2021 | 12.33 Mn |
| Jun 30, 2021 | 12.64 Mn |
| Mar 31, 2021 | 8.52 Mn |